180 Life Sciences Corp.

NasdaqCM ATNF

180 Life Sciences Corp. Current Liabilities for the quarter ending September 30, 2024

180 Life Sciences Corp. Current Liabilities is NA for the quarter ending September 30, 2024. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

180 Life Sciences Corp. Current Liabilities for the quarter ending September 30, 2023 was USD 4.81 M, a 1.73% change year over year.
180 Life Sciences Corp. Current Liabilities for the quarter ending September 30, 2022 was USD 4.72 M, a -80.50% change year over year.
180 Life Sciences Corp. Current Liabilities for the quarter ending September 30, 2021 was USD 24.22 M.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqCM: ATNF

180 Life Sciences Corp.

CEO	Sir Marc Feldmann Ph.D.
IPO Date	June 27, 2017
Location	United States
Headquarters	Building 4
Employees	4
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Key trends

Past 5 years